Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Enlivex ( (ENLV) ) has shared an announcement.
Enlivex Therapeutics has received authorization from the Israeli Ministry of Health to initiate a Phase I trial of its Allocetra therapy for TMJ osteoarthritis. The trial at Sheba Medical Center will evaluate the safety and efficacy of Allocetra in patients with limited response to existing treatments, potentially offering a novel solution for a condition with significant unmet medical need.
More about Enlivex
Enlivex is a clinical-stage immunotherapy company focused on macrophage reprogramming. It is developing Allocetra, a universal cell therapy aimed at restoring macrophages to their homeostatic state, addressing life-threatening conditions such as solid cancers and sepsis.
YTD Price Performance: -53.70%
Average Trading Volume: 254,634
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $27.49M
Find detailed analytics on ENLV stock on TipRanks’ Stock Analysis page.
